EMI

Encore Medical filed Amendment No. 8 to its S-1 for an IPO of 3,000,000 shares at $5.00 per share…

The IPO is a lifeline to fund clinical trials and repay debt, but the company remains pre-revenue in the U.S. with a going concern warning. Monitor for FDA trial enrollment updates and CE Mark…

Encore Medical filed Amendment No. 7 to its S-1 for an IPO of 3,000,000 shares at $5.00 per share…

Monitor the IPO pricing and closing — if successful, the $10.6M net proceeds will fund the stroke trial through key milestones but leave the migraine trial underfunded. The company's survival…

Encore Medical, Inc. filed Amendment No. 5 to its S-1 registration statement for an IPO of…

The IPO provides a critical capital infusion but does not eliminate the going concern risk given the company's minimal cash ($34,619) and substantial debt obligations. The $12.6M net proceeds are…

Encore Medical, Inc. filed an amended S-1/A registration statement to update the filing fee table…

This amendment confirms pricing stability at $5.00 per share despite prior uncertainty, but the increased warrant strike price suggests underwriter negotiation leverage. The lack of financial…